The International Myeloma Foundation Mourns the Loss of Accomplished Attorney and Longtime Board Member Benson Klein Read more about The International Myeloma Foundation Mourns the Loss of Accomplished Attorney and Longtime Board Member Benson Klein Add new comment
EU Approves SARCLISA® (isatuximab-irfc) for the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Read more about EU Approves SARCLISA® (isatuximab-irfc) for the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Add new comment
Blenrep (belantamab mafodotin) Approved in the EU for Relapsed/Refractory Multiple Myeloma Read more about Blenrep (belantamab mafodotin) Approved in the EU for Relapsed/Refractory Multiple Myeloma Add new comment
U.S. FDA Extends Review Period for Blenrep (belantamab mafodotin) for Relapsed or Refractory Myeloma Read more about U.S. FDA Extends Review Period for Blenrep (belantamab mafodotin) for Relapsed or Refractory Myeloma Add new comment
Health Canada Approves Blenrep (belantamab mafodotin) Combinations for Relapsed or Refractory Multiple Myeloma Read more about Health Canada Approves Blenrep (belantamab mafodotin) Combinations for Relapsed or Refractory Multiple MyelomaAdd new comment
European Commission Approves Darzalex Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma Read more about European Commission Approves Darzalex Subcutaneous Monotherapy for High-Risk Smoldering Multiple MyelomaAdd new comment
The International Myeloma Foundation Brings the Patient Voice and Science to FDA-ODAC Meeting; Advocates for BLENREP® (belantamab mafodotin) in Triplet Drug Combinations for the Treatment of Relapsed/Refractory Myeloma Read more about The International Myeloma Foundation Brings the Patient Voice and Science to FDA-ODAC Meeting; Advocates for BLENREP® (belantamab mafodotin) in Triplet Drug Combinations for the Treatment of Relapsed/Refractory Myeloma Add new comment
July 2025 – Myeloma News from the Journals Read more about July 2025 – Myeloma News from the JournalsAdd new comment
The International Myeloma Foundation’s Brian D. Novis Research Grants: Celebrating 30 Years of Paving the Way for Transformative Breakthroughs in Myeloma Research Read more about The International Myeloma Foundation’s Brian D. Novis Research Grants: Celebrating 30 Years of Paving the Way for Transformative Breakthroughs in Myeloma ResearchAdd new comment
European Hematology Association (EHA) and the European Myeloma Network (EMN) Include Pepaxti in New Clinical Practice Guidelines for Relapsed/Refractory Multiple Myeloma (RRMM) Read more about European Hematology Association (EHA) and the European Myeloma Network (EMN) Include Pepaxti in New Clinical Practice Guidelines for Relapsed/Refractory Multiple Myeloma (RRMM)Add new comment
